Morgan Stanley analyst Erin Wright has reiterated their bullish stance on DGX stock, giving a Buy rating on March 17.
Erin Wright has given his Buy rating due to a combination of factors that reflect a positive outlook for Quest Diagnostics. The company is expected to maintain its long-term growth targets, with revenue growth driven by both organic means and mergers and acquisitions. Quest Diagnostics has been outperforming its previous growth expectations, particularly in terms of mergers and acquisitions, which have contributed significantly to its revenue.
Additionally, the company is anticipated to achieve operating margin expansion through favorable pricing and productivity savings initiatives. Despite some potential challenges, such as regulatory changes and market conditions, Quest Diagnostics is seen as having strong medium and long-term growth prospects. This is further supported by its strategic capital deployment and relative insulation from broader policy uncertainties, making it an attractive investment opportunity.
In another report released on March 17, Robert W. Baird also maintained a Buy rating on the stock with a $190.00 price target.
DGX’s price has also changed moderately for the past six months – from $155.380 to $173.480, which is a 11.65% increase.